Unexpected remission of hepatocellular carcinoma (HCC) with lung metastasis to the combination therapy of thalidomide and cyproheptadine: Report of two cases and a preliminary HCC cell line study

BMJ Case Reports

Volumn , Issue , 2012, Pages

  Feng, Yu Min ^a   Feng, Chin Wen ^b   Chen, Solomon Chih Cheng ^a   Hsu, Cheng Da ^a  

^a CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CYPROHEPTADINE; EPIRUBICIN; THALIDOMIDE;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER REGRESSION; CASE REPORT; CELL VIABILITY; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG CYTOTOXICITY; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SKIN PRURITUS; TREATMENT DURATION; TUMOR VOLUME;

EID: 84872134136     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2012-007180     Document Type: Article

References (15)

1. Jan CF, Chen CJ, Chen HH. Causes of increased mortality from hepatocellular carcinoma in high incidence country: Taiwan experience. J Gastroenterol Hepatol 2005;20 :521-6.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
3. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-90.
4. Yau T, Chan P, Wong H, et al. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma. Oncology 2007;72:67-71.
5. Yabu T, Tomimoto H, Taguchi Y, et al. Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood 2005;106:125-34.
6. Baek JY, Hur W, Wang JS, et al. Selective COX-2 inhibitor, NS-398, suppresses cellular proliferation in human hepatocellular carcinoma cell lines via cell cycle arrest. World J Gastroenterol 2007;13:1175.
7. Kardinal CG, Loprinzi CL, Schaid DJ, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990;65:2657-62.
8. Jangi SM, Asumendi A, Arlucea J, et al. Apoptosis of human T-cell acute lymphoblastic leukemia cells by diphenhydramine, an H1 histamine receptor antagonist. Oncol Res Featur Preclin Clin Cancer Ther, 14, 2004;7:363-72.
9. Soule BP, Simone NL, DeGraff WG, et al. Loratadine dysregulates cell cycle progression and enhances the effect of radiation in human tumor cell lines. Radiat Oncol 2010;5:1-12.
10. Medina MA, García de Veas R, Morata P, et al. Chlorpheniramine inhibits the synthesis of ornithine decarboxylase and the proliferation of human breast cancer cell lines. Breast Cancer Res Treat 1995;35:187-94.
11. Mao X, Liang SB, Hurren R, et al. Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood 2008; 112:760-9.
12. Paoluzzi L, Scotto L, Marchi E, et al. The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor. Br J Haematol 2009;146:656-9.
13. Kapur S, Zipursky RB, Jones C, et al. Cyproheptadine: a potent in vivo serotonin antagonist. Am J Psychiatry 1997;154:884.
14. Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med 1998; 16:615-19.
15. Soll C, Jang JH, Riener MO, et al. Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology 2010;51:1244-54.